研究报告—药品流通（附发展环境、全景概览、竞争格局及发展前景预测）

Core Insights - The pharmaceutical distribution industry is a crucial part of the national healthcare system and is essential for public health and safety. The wholesale segment plays a key role in reducing distribution costs and drug prices [1][3]. Market Overview - The pharmaceutical distribution market in China is projected to reach a sales volume of 29,470 billion yuan in 2024, with wholesale sales accounting for 22,970 billion yuan (77.94%) and retail sales for 6,500 billion yuan (22.06%) [1][4]. - The regional distribution of sales in 2024 is as follows: East China 36.3%, Central South 27.0%, North China 15.2%, Southwest 13.4%, Northeast 4.3%, and Northwest 3.8%. The three major regions (East, Central South, North) account for 78.5% of total sales [1][4]. Product Segmentation - In terms of product categories, Western medicine sales dominate with a share of 70.8%, followed by traditional Chinese medicine at 14.6%, medical devices at 7.7%, Chinese herbal medicine at 2.4%, chemical reagents at 0.6%, glass instruments at less than 0.1%, and other categories at 3.9% [1][4]. Industry Structure - The pharmaceutical distribution industry consists of three main segments: upstream (manufacturers of drugs and medical devices), midstream (pharmaceutical distribution companies), and downstream (medical institutions, pharmacies, and consumers) [3][8]. - The industry operates under two primary distribution models: manufacturer-wholesaler-medical institution-consumer and manufacturer-wholesaler-pharmacy-consumer [3][6]. Competitive Landscape - In the first half of 2025, major pharmaceutical distributors such as China National Pharmaceutical Group, Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong reported revenues of 286.04 billion yuan, 141.59 billion yuan, 131.87 billion yuan, and 81.11 billion yuan respectively [5]. - The future development of China's pharmaceutical distribution is expected to focus on sustainable growth, ensuring the provision of safe and cost-effective medicines to the public [5].